Invasive Meningococcal Disease (IMD) Update

Claire Jarashow PHD, MPH
Epidemic Intelligence Service Officer
Acute Communicable Disease Control
Los Angeles County Department of Public Health
cjarashow@ph.lacounty.gov
2016-17 SoCal Outbreak

- Largest known IMD outbreak among MSM in US
- 31 outbreak-associated cases
- Multiple local health jurisdictions
  - City of Long Beach
  - Los Angeles County
  - Orange County
  - Ventura County
# IMD Case Description (n=31)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Number (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>28 (90%)</td>
</tr>
<tr>
<td>MSM (% of males)</td>
<td>23 (82%)</td>
</tr>
<tr>
<td>Median age (range)</td>
<td>32 (17-76)</td>
</tr>
<tr>
<td>Hospitalized</td>
<td>30 (97%)</td>
</tr>
<tr>
<td>Known HIV infection</td>
<td>5/29 (17%)</td>
</tr>
<tr>
<td>Deaths</td>
<td>4 (13%)</td>
</tr>
</tbody>
</table>
Epidemic Curve

Number of cases

Weeks since start of the outbreak

LAC case
LB/OC/VC case
Out of state w/ LAC exp
Symptoms and Hospital Stay of LAC cases (n= 14)

<table>
<thead>
<tr>
<th>Symptom</th>
<th>2016-17 n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea or vomiting</td>
<td>10 (71)</td>
</tr>
<tr>
<td>Triad (fever, stiff neck, altered sensorium)</td>
<td>7 (50)</td>
</tr>
<tr>
<td>Length of hospital stay (days)</td>
<td>8 (6 – 95)</td>
</tr>
</tbody>
</table>
Clinical Presentation of Outbreak Cases

<table>
<thead>
<tr>
<th></th>
<th>Cases (n=27)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meningococcemia</td>
<td>63%</td>
</tr>
<tr>
<td>Meningitis</td>
<td>37%</td>
</tr>
</tbody>
</table>
LAC Vaccine Recommendations

• All HIV-infected persons should receive:
  • 2 doses of the conjugate meningococcal (MenACWY) vaccine at least 8 weeks apart and a booster 5 years later* and every 5 years thereafter throughout life.

• All MSM who are not HIV-infected should receive:
  • single MenACWY vaccine dose (Menveo® or Menactra®) or a booster if the most recent dose was given ≥5 years ago.

*If the most recent dose was received before age 7 years, the first booster dose should be administered 3 years after the initial dose and then every 5 years thereafter throughout life.

Note: MenACWY vaccine is included on the AIDS Drug Assistance Program (ADAP) formulary.
Provider Guidance

• Implement evidence-based practices to ensure completion of the 2-dose vaccination schedule for all HIV-infected persons.
  • Examples include reminder-recall or co-scheduling
  • Track completion rates
• Ensure MSM clinic staff are completely vaccinated
• Refer MSM for free MenACWY vaccine if vaccination is not feasible at their primary care provider
Vaccination Information

Meningococcal Vaccine Dosing and Schedule- updated CDPH chart describing timing of doses for high-risk populations
http://eziz.org/assets/docs/IMM-1218.pdf

Free Meningococcal Vaccine for all uninsured/underinsured MSM in LAC. Find a location here:
Eculizumab CDC Health Advisory

- Eculizumab (Soliris®) commonly prescribed for treatment of
  - atypical hemolytic uremic syndrome (aHUS)
  - paroxysmal nocturnal hemoglobinuria (PNH)
- Patients receiving Eculizumab have 1,000-2,000 fold greater risk of
  IMD compared to general population
- ACIP recommends meningococcal vaccination for all patients receiving eculizumab
- Meningococcal conjugate (MenACWY) vaccine targets serogroups
  A, C, W, and Y, but provides no protection against nongroupable N. meningitidis
- Consider antimicrobial prophylaxis for duration of eculizumab therapy
Reporting

• Report **suspect cases** (positive Gram stain, don’t wait until culture is positive) **immediately** to ACDC by phone:
  (213) 240-7941 8am-5pm
  (213) 974-1234 after hours

• Forms to complete and fax after the call found here: